ショウレイ ホウコク ジョウガク シュヨウ セツジョゴ ノ ジッシツ ケッソン ニ タイスル ホテツテキ シュウフク ジュン チタンセイ スパイラル ジンコウ シコン オ ギガク イジ ソウチ トシテ テキオウシタ 1ショウレイ

上顎歯肉癌治療後の口蓋半側欠損症例(72歳,男性)に対する義顎の維持装置として,私供は,最近入手し得た純チタン製スパイラル人工歯根(Chercheve,仏)を使用し,義顎の装用性に良好な結果を得た。外科手術後の特殊義歯である義顎の維持装置としての人工歯根応用の報告は極めて少ないが,このような治療が一般的になるならば義歯はもとより,顎補綴治療にとってその臨床的意義は大きいものと考える。journal articl

Clinical studies on tosufloxacin (TFLX) in urology

横浜市立大学泌尿器科およびその関連施設を加えた13施設で, TFLXを使用して有効性と安全性について検討した.1)女子急性単純性膀胱炎164例の総合有効率は98.78%であった.2)男子急性単純性膀胱炎4例, 急性単純性腎盂腎炎3例, 非淋菌性尿道炎1例, 複雑性尿路感染症7例にも投与して100%の有効率がえられた.3)原因菌の中で, グラム陰性菌は100%の消失率で, グラム陽性菌は90.60%の消失率であった.4)副作用発現は5例にみられ, その発現率は2.42%であったWe clinically evaluated the usefulness of a new oral antimicrobial agent, TFLX, in the field of urology. The dose administered was 150 mg t.i.d and the duration of administration was 3 days. The clinical effect was evaluated according to the criteria of the Japanese UTI committee. The clinical response obtained on 164 female patients with acute simple cystitis was excellent in 118, moderate in 44 and poor in 2 patients. The efficacy rate was 98.78%. The clinical response obtained on 4 male patients with acute simple cystitis was excellent in 2 and moderate in 2 patients. The efficacy rate was 100%. The clinical response obtained on 3 female patients with simple pyelonephritis was excellent in 2 and moderate in 1 patient. The efficacy rate was 100%. The clinical response obtained on one patient with non-gonococcal urethritis was excellent by doctor's evaluation. The clinical response obtained on 7 patients with complicated UTI was excellent in 3 and moderate in 4 patients. The efficacy rate was 100%. Three patients complained of stomach distress or malaise and 2 patients developed rash. No abnormal laboratory data were observed. Thus, TFLX appears to be safe and suitable for use in the field of urology

放射線に関する意識調査

In Japan, cancer treatment is expected to continue increasing as the number of elderlypeople increases. Since surgery is a heavy physical burden for the elderly, pain afteroperation and exhaustion of physical fitness are major problems in quality of life. On theother hand, the number of radiation therapy cases is expected to increase because radiationtherapy is less invasive and reduces physical burden. However, there are many people whohave a sense of disgust or fear about radioactive materials and radiation because Japan isthe only country to have experienced atomic bombs and has experienced the FukushimaDaiichi Nuclear Power Station accident caused by the Tohoku Earthquake.In this study, we investigated the consciousness of these students about radiation inFaculty of International Communication and Economics and Management as a student whoseems to have no opportunity to learn about radiation at universities, and the Faculty of Pharmaceutical Sciences and Health and Medical Sciences as a medical science coursestudent.The results suggest that both medical sciences students have knowledge about radiationbecause they have an opportunity to learn about radiation, but those who have noopportunity to learn about radiation are scared of radiation with vague knowledge. Inaddition, in the Faculty of Pharmaceutical Sciences, it was found that the difference inradiation consciousness with radiological technologists was smaller in upper grade students.On the other hand, many students in the Faculty of Humanities had a scary image ofradiation. From this, it can be considered that patients will become anxious about radiationas the relationship between radiation and medical treatment further increases. It isimportant that medical personnel such as pharmacists acquire correct knowledge ofradiation. We also think that there is a role to support treatment from the patient\u27sstandpoint.〔査読有り〕の原著論文 責任著者：鍛治　

イオン交換体等吸着剤の処理による無加熱臭果汁製造に関する基礎的研究

application/pdfArticledepartmental bulletin pape

Clinical early phase II study of bicalutamide (Casodex) in patients with prostatic cancer

ビカルタミド1日1回50mg群, 80mg及び100mgを12週間投与する3群比較の無作為化非盲検試験を実施した. 1)登録症例は124例で, 適格例は122例であった. 2)総合効果における奏効率は50mg群, 80mg群及び100mg群でそれぞれ50.5%, 61.0%及び53.7%であった. 3)PSAに対する奏効率は50mg群, 80mg群及び100mg群でそれぞれ84.2%, 92.7%及び97.6%であった. 4)副作用発現率は3群ほぼ6割で副作用による中止例は80mg群の1例のみで, 安全度において3群間に有意差はなかった.主な副作用は乳房腫脹, 乳房圧痛等であったTo investigate the efficacy and safety of bicalutamide (Casodex(R)) with its clinically recommended dose, the randomized early phase II study was performed in 124 patients with prostatic cancer (stage C, D). The patients were given 50, 80 or 100 mg of bicalutamide orally once a day in fixed doses for 12 weeks ; 122 patients were eligible for evaluation. The overall response rate was 50.0% (20/40); 61.0% (25/41) and 53.7% (22/41) in the 50 mg, 80 mg and 100 mg groups, respectively. The response rate in prostate lesion, bone and lymph node metastases was slightly higher in the 80 mg group than in the 50 mg and 100 mg groups. The proportion of patients showing a response with regard to serum PSA (CR and PR) was 84.2, 92.7 and 97.6% in the 50, 80 and 100 mg groups, respectively. The incidence of adverse reactions was 65.0, 61.0 and 61.0% in the 50, 80 and 100 mg groups, respectively, and there was no significant difference in overall safety rating in the three groups. Frequent adverse reactions were gynecomastia and breast pain. Only one patient in the 80 ing group was withdrawn due to shortness of breath. Serum concentrations of LH, testosterone and estradiol increased significantly after treatment. Bicalutamide was concluded to be effective and well tolerated in patients with prostatic cancer, and its recommended dose was 80 mg once daily

Influence of Various Factors on Deterioration of Repaired Concrete Structures (3) : Influence of Exposure Conditions of Reinforced Concrete

特集 都市基盤の安全とICUSの活